Summit Therapeutics Refocuses on Oncology Drug

Key Takeaways

• Summit signed an agreement to sell ridinilazole to Biossil for $500,000 upfront and up to $104.5 million in regulatory and commercial milestones, plus tiered royalties.
• Leadership said the sale lets Summit prioritize ivonescimab and its oncology strategy.
• Ri-CoDIFy showed a higher Sustained Clinical Response rate versus vancomycin but missed superiority on the primary endpoint.
• FDA accepted Summit's BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC post-TKI, with a PDUFA goal date of November 14, 2026.

Summit ridinilazole sale at a glance

Field	Detail
Seller	Summit Therapeutics Inc. (NASDAQ: SMMT)
Buyer	Biossil, Inc. (Toronto)
Asset	Ridinilazole, investigational Phase III precision antibiotic
Economics	$500,000 upfront; up to $104.5 million milestones; tiered royalties
Announcement	July 14, 2026
Oncology focus	Ivonescimab (PD-1/VEGF bispecific); FDA BLA accepted; PDUFA Nov. 14, 2026
Prior CDI trial	Ri-CoDIFy Phase III (NCT03595566), completed

What did Summit announce on July 14, 2026?

Summit Therapeutics said it signed an agreement with Biossil for the sale of ridinilazole, according to Summit Therapeutics' July 14 Business Wire release. Biossil is described as an AI-native biopharma company focused on late-stage programs in life-threatening indications.

Under the deal terms, Summit will receive $500,000 upfront and up to $104.5 million in regulatory and commercial milestones, plus tiered royalties on net sales. Summit stressed that ridinilazole is not approved and that regulators, including the FDA, have not evaluated its safety and efficacy for marketing authorization.

How does the sale support Summit's oncology focus?

Chairman and Co-CEO Robert W. Duggan said Biossil is well positioned to advance ridinilazole while Summit continues prioritizing its core oncology strategy and ivonescimab development. That message matches Summit's earlier strategic shift away from anti-infectives after in-licensing ivonescimab from Akeso.

In plain terms, the antibiotic is no longer the company's growth engine. The near-term value story sits with ivonescimab in solid tumors, especially non-small cell lung cancer.

What did Ri-CoDIFy show for ridinilazole?

Ridinilazole was previously evaluated in Summit's Phase III Ri-CoDIFy study in patients with C. difficile infection. The study showed a higher observed Sustained Clinical Response rate than vancomycin but did not meet the primary endpoint for superiority within the established time boundaries, Summit said in the July wire.

Sustained Clinical Response means clinical response of the treated CDI episode with no recurrence through 30 days after the end of treatment. Summit also said exploratory data suggested microbiome preservation, lower recurrence rates, reduced toxin production, dosing convenience, and tolerance versus vancomycin, but those findings require further study.

The completed Phase III comparison of ridinilazole versus vancomycin is registered as ClinicalTrials.gov study NCT03595566, which lists 759 enrolled participants and a completed status.

Where does ivonescimab stand with the FDA?

Summit's oncology priority is clearer in its SEC disclosures. In a January 29, 2026 Form 8-K, Summit reported that the FDA accepted for filing its Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated locally advanced or metastatic non-squamous NSCLC after tyrosine kinase inhibitor therapy. The PDUFA goal action date is November 14, 2026, per Summit's January 29, 2026 Form 8-K.

Ivonescimab is an investigational PD-1/VEGF bispecific antibody. It is not approved in Summit's license territories, including the United States. Summit is also advancing broader Phase III work, including HARMONi-GI3 in metastatic colorectal cancer, registered as ClinicalTrials.gov study NCT07228832.

What remains open after the divestiture?

Biossil said it plans to continue clinical development of ridinilazole. Summit did not disclose a new registrational timeline for the antibiotic under Biossil's ownership. For Summit investors and trial watchers, the practical follow-ups are the FDA review of the ivonescimab BLA and upcoming HARMONi-program readouts.

For related U.S. regulatory and trial context, see NovaPharma coverage of FDA human-factors guidance for marketing submissions, Moderna's mRNA-1083 Phase 3 flu-COVID data, and J&J's Phase 3 TREMFYA ulcerative colitis results.

Why does the deal matter for C. difficile and oncology pipelines?

C. difficile remains a high-burden healthcare-associated infection, and microbiome-sparing antibiotics are still scarce. Moving ridinilazole to a buyer that says it will keep developing the asset may reopen a stalled path, but approval is not guaranteed.

For Summit, the cleaner story is concentration risk: one bispecific antibody now carries the company's near-term regulatory weight. That makes the November 14, 2026 PDUFA date the calendar event that matters most after the antibiotic sale.

Frequently Asked Questions

Primary Sources

1. Summit Therapeutics: Sale of ridinilazole to Biossil (July 14, 2026)
2. Summit Therapeutics Form 8-K: FDA BLA acceptance for ivonescimab (January 29, 2026)
3. ClinicalTrials.gov: Ri-CoDIFy ridinilazole vs vancomycin (NCT03595566)
4. ClinicalTrials.gov: HARMONi-GI3 ivonescimab in mCRC (NCT07228832)